Overview

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Status:
Completed
Trial end date:
2019-01-10
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
Phase:
Phase 2
Details
Lead Sponsor:
Genmab
Seagen Inc.
Collaborator:
Genmab
Treatments:
Tisotumab vedotin